290650 - L & C BIO Co., Ltd.

290650 Summary

Biopharma

Stock Price & Overview

₩47,900 -700 (-1.44%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩47,900 ≈ US$34 · Market cap ₩1.3tn (≈ $923m)

290650 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total Revenue	85.5	72.0	65.9	52.6	45.7	33.0	29.2	21.2	17.9	11.8
Cost of Revenue	40.1	36.4	32.1	25.6	17.2	13.4	10.5	7.9	6.8	4.8
Gross Profit	45.4	35.7	33.9	27.0	28.5	19.6	18.7	13.4	11.1	7.0
Selling, General & Administrative	41.0	31.8	30.9	17.5	15.3	12.2	9.6	7.9	6.3	4.9
Operating Income	4.4	3.9	2.9	9.5	13.2	7.3	9.0	5.5	4.9	2.1
Finance Income	34.3	5.0	5.6	1.9	0.8	1.4	1.0	0.3	0.1	0.2
Finance Costs	125.1	16.9	8.6	6.3	0.9	1.2	0.2	0.1	0.4	0.4
Pretax Income	-160.0	139.8	58.0	4.6	17.1	12.9	9.9	5.9	4.6	2.2
Income Tax Expense	-21.7	-5.1	13.2	-1.1	1.5	0.8	1.5	-0.8	0.9	0.2
Net Income	-138.2	141.5	44.5	5.7	15.6	12.1	8.5	5.1	3.8	2.0
Total Comprehensive Income	-138.0	139.2	42.1	7.0	16.6	11.9	8.3	5.1	3.9	2.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total Assets	456.6	472.1	257.3	199.7	107.4	80.6	66.2	57.4	20.5	15.7
Current Assets	139.2	130.2	130.4	64.3	47.6	45.5	46.1	49.9	18.1	13.6
Cash & Cash Equivalents	30.9	18.3	14.9	6.6	17.4	22.3	12.8	21.6	3.1	0.4
Inventories	42.8	46.8	46.3	34.2	12.3	8.1	6.2	5.6	5.4	5.1
Trade Receivables	25.7	54.2	22.6	16.8	14.8	9.3	10.1	7.5	6.0	4.4
Non-current Assets	317.4	342.0	127.0	135.4	59.8	35.1	20.1	7.5	2.4	2.1
Property, Plant & Equipment	106.6	97.0	74.7	53.1	17.9	9.5	7.3	4.9	1.4	1.4
Intangible Assets	127.8	199.2	1.5	3.6	1.1	0.2	0.2	0.1	0.1	0.1
Total Liabilities	248.1	180.9	104.5	91.9	14.1	19.3	6.0	4.6	3.7	5.6
Current Liabilities	237.8	154.7	101.8	18.7	5.6	3.7	3.4	3.1	3.3	2.2
Non-current Liabilities	10.3	26.2	2.6	73.2	8.5	15.6	2.6	1.5	0.4	3.5
Total Equity	208.5	291.3	152.9	107.8	93.3	61.3	60.3	52.8	16.8	10.0
Share Capital	12.4	11.4	11.4	11.4	11.4	11.0	3.7	3.6	1.5	1.3
Retained Earnings	99.3	218.7	79.6	36.9	33.3	20.6	20.7	13.7	8.4	4.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from Operating Activities	12.6	-8.6	-12.1	-6.1	10.9	7.4	6.4	3.8	3.8	-0.2
Cash from Investing Activities	-32.9	-21.9	24.6	-83.6	-20.5	0.8	-15.8	-16.8	-0.6	-4.2
Purchase of Property, Plant & Equipment	15.8	4.7	24.5	37.5	10.3	3.0	2.0	4.7	0.3	0.6
Cash from Financing Activities	32.1	33.8	-4.2	78.9	4.7	1.3	0.5	31.4	-0.5	4.2
Dividends Paid	1.1	2.3	1.1	1.1	1.1	0.7	—	—	—	—
Net Change in Cash	11.8	3.3	8.3	-10.8	-4.9	9.5	-8.9	18.5	2.7	-0.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	38.8	30.3	24.7	22.6	20.6	17.8	19.1	18.5	17.9	16.6
Cost of Revenue	15.2	11.9	11.6	9.4	11.2	7.9	9.9	9.5	8.7	8.3
Gross Profit	23.6	18.4	13.1	13.2	9.4	9.8	9.2	9.1	9.2	8.2
Selling, General & Administrative	15.0	12.4	11.1	10.3	9.6	10.3	9.8	8.9	7.9	6.6
Operating Income	8.6	6.0	2.0	2.9	-0.2	-0.4	-0.6	0.2	1.3	1.7
Finance Income	31.7	1.5	5.8	21.7	6.0	0.9	0.9	-0.8	3.2	1.7
Finance Costs	47.2	4.4	27.4	76.4	20.0	1.3	9.2	4.9	2.1	1.4
Pretax Income	-7.1	3.0	-94.0	-51.3	-14.0	-0.9	139.9	-5.7	1.5	2.0
Income Tax Expense	21.0	0.3	-21.5	0.0	0.1	-0.2	-6.1	0.1	0.4	0.1
Net Income	-28.1	2.7	-72.0	-51.3	-14.3	-0.6	143.8	-5.8	1.1	1.9
Total Comprehensive Income	-27.3	4.2	-71.1	-50.4	-15.9	-0.6	140.8	-5.6	1.6	1.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	477.4	467.1	456.6	497.9	489.7	432.1	475.6	251.8	258.0	264.6
Current Assets	172.9	155.0	139.2	143.0	141.9	89.9	130.2	101.8	116.6	124.5
Cash & Cash Equivalents	36.4	43.8	30.9	31.1	50.6	7.8	18.3	21.0	8.6	10.1
Inventories	40.4	41.7	42.8	45.6	45.8	47.5	46.8	49.2	48.5	46.5
Trade Receivables	34.5	29.5	25.7	26.4	24.8	24.1	54.2	22.9	24.7	22.6
Non-current Assets	304.5	312.1	317.4	355.0	347.7	342.2	345.4	150.0	141.3	140.2
Property, Plant & Equipment	122.4	113.8	106.6	99.0	97.0	95.3	97.0	77.3	74.2	73.8
Intangible Assets	131.2	127.7	127.8	200.2	200.2	199.5	199.2	1.5	1.3	1.4
Total Liabilities	142.2	253.9	248.1	231.2	166.1	138.7	180.9	98.1	98.8	107.1
Current Liabilities	130.1	243.8	237.8	205.4	136.2	112.6	154.7	91.7	95.1	103.9
Non-current Liabilities	12.1	10.1	10.3	25.8	30.0	26.1	26.2	6.4	3.7	3.2
Total Equity	335.2	213.2	208.5	266.7	323.5	293.3	294.7	153.7	159.2	157.5
Share Capital	13.5	12.5	12.4	12.4	12.4	11.4	11.4	11.4	11.4	11.4
Retained Earnings	72.6	100.7	99.3	175.4	226.8	240.6	222.2	78.6	83.8	82.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	8.1	8.2	6.1	3.8	1.4	1.3	0.4	-2.3	-8.0	1.3
Cash from Investing Activities	-15.9	3.8	-8.3	-5.9	-5.9	-12.8	-38.8	14.7	8.8	-6.7
Purchase of Property, Plant & Equipment	11.0	7.6	8.5	2.9	3.5	0.9	-0.8	3.0	2.1	0.5
Cash from Financing Activities	0.3	0.6	1.2	-17.5	47.5	0.9	35.8	-0.1	-2.4	0.6
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	-7.6	12.6	-1.0	-19.5	42.8	-10.5	-2.7	12.3	-1.5	-4.8

Consolidated (CFS), from DART. 10 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

290650 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	85.5	+18.7%	+17.6%	+21.0%	—
Operating income	4.4	+14.1%	-22.5%	-9.6%	—
Net income	-138.2	—	—	—	—
EPS	₩-5,126	—	—	—	—
Operating cash flow	12.6	—	—	+11.1%	—
Shareholders' equity	208.5	-28.4%	+24.6%	+27.8%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

290650 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	53.1%	49.5%	51.4%	51.3%	62.3%	59.3%
Operating margin	5.2%	5.4%	4.4%	18.0%	28.8%	22.2%
Net margin	-161.7%	196.4%	67.6%	10.8%	34.1%	36.8%
Return on equity	-55.3%	63.7%	34.2%	5.7%	20.2%	20.0%
Return on assets	-29.8%	38.8%	19.5%	3.7%	16.6%	16.6%
Operating cash flow / revenue	14.7%	-11.9%	-18.4%	-11.6%	23.9%	22.5%
Capex / revenue	18.5%	6.5%	37.2%	71.4%	22.4%	9.1%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 290650

Symbol	Last Price
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%
003090Daewoong Co., Ltd.	₩16,860 -2.0%
086450Dong Kook Pharmaceutical Co., Ltd.	₩21,600 -0.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.